这才是19年的几个关键性时时，它将在未来的发展几年底体现普外手术治疗丝机人市场的。

现有医疗管理设备这个行业热天气门的销售市場产品之一是整形科系统人。依照Allied Market Research的1份通知单，该科技领域销售市場空间在20110年为0.563000万加元，平均到2021年将增涨至987.37亿英镑，预计过程中的分手后复合年增涨率为8.5%。2020年是内科电脑人技术应用的出现增长额元年。MD+DI小程序介绍了2020年内窥镜手术电脑人区域几个重要性時刻。

达芬奇广州POS机人：促进涨钱攻略

理智急诊科自2000年获得了FDA批准书整个市场销售近些年，直到是小手术机人整个市场的带领者。或许，竞争与合作白热化敌人己经慢慢的诞生并增长。理智急诊科的管理层表达出来，渐渐竞争与合作白热化愈来愈越白热化，新产品研发设备的投入市场，平台应该会在“打折攻略”来兑换更好 的贸易市场，也也就是加强成本商谈和商谈时段的变长。该公司的带表，等动态图片也有可以引起毛利润上下波动。但讲一系列原来看做其销售价过高的医院机构和医院中心站讲，有可以是个号消息提示。

CMR的2大顺利

公司总部地属英国媒体剑桥的CMR去年过得还不错。六月，机构在C轮项目融资中募集了2.43000万元，主要用于它的器机人外挂整形装置设备商业服务化。上月，该平台达成了向建在印度是普纳的星辰保养大医院（Galaxy Care Hospital）出卖其首台环保设备的买卖交易。CMR建立于5年里，并在记者上发表表述，梦想2021能能够 FDA的教育部认证。

Verb：新CEO到任

Verb是强生装修平台的Ethicon部分和verly活力安全科学的课装修平台的中外合资中小企业。仅仅相互合作方式发生在verly（前谷歌浏览器活力安全科学的课部分）与大部分生物医药科技有限厂家装修平台相互合作方式的那时候。然而Verb在确立之初就独树一帜，但该装修平台在二零一九年始终非常的淡雅。殊不知，近几年6月，Verb再者变成今日头条新闻新闻，在当时它敲定库尔特•阿扎尔巴津（Kurt Azarbarzin）将就任新总截兼总裁执行力官。阿扎尔巴津曾是SurgiQuest的顶尖总裁实行程序官，有一天2010年被Conmed（康美）以2.65000万澳元并购。Azarbarzin就是一个女装大牌英雄，他接任了Verb前顶尖总裁实行程序官ScottHuennekens，后面于2018年2019年的时候离去新公司。

泰坦医疗机构（Titan Medical）：关闭建设

泰坦医院司（Titan Medical）在行动机器人图片人做手术设备上会碰到打了个个极大的障碍性，并在1月中下旬公布撤消所以关于该网站料工费和用时的预測，终止开放。Titan Medical显示，单位融资过高是引发迟缓的现象。当然，泰坦并未让它变慢。该单位正寻求合作募集2五百万人民币 的经济，以鼓励仅仅中长跑的设计返回到正道。

XACT：获取FDA的什么时候上市审批

XACT电脑人工司的近视手术电脑人收获FDA香港上市签发。该控制系统在CT修复系统下经皮进入冶疗方式中能够食用。这里北京分我司座落在非洲的近视手术器机人我司，幕后的更让人赞不绝口的因素是，它是正式启动医疗器械创新网场景图片设计方案和汽车导航，不用速腾自动化档使用的机械人人控制系统，会自动化引流各项机器设备在一类别诊疗医疗器械创新网和转变症中展开插入图和偏向使用。

强生：34亿人民币 采购Auris

强生以34亿人艮币先进（相当于人艮币230亿人民币）对价收够整形手术机械人集团公司Auris，若是实现部分里数碑，还必须支付行业至少23.五亿欧元的格外或有工程款。这也将成為强生在并购整形科操作图片软件设备人科技联合开发单位Orthotaxy之久一整年里二次在这些领域行业的出手。

Auris 是由整形科机器人视频人先驱者弗里德里克·莫尔（Frederic Moll）创建人，他还也是亚洲地区内窥镜手术电脑人领先Intuitive Surgical（思维普外）的携手创办人产品之一，普通地区的达芬奇电脑人如今占居了很高比例的行业市场。Frederic Moll也在回收后下载强生。

Auris用心于1.肺癌丝机人水平，其重要服务是款名里Monarch的，可由内科牙医利用有一款 掌控模块使用掌控的丝机人，教育引导有一款 带着摄录机的探究镜进人患儿身体内，要用于疾病诊断性和治愈性的支气管镜查检，这款查检中牙医需将设备插入图患儿的鼻内或嘴巴。

美敦力：建造医疗服务机械人王国

费改后24日，美敦力在进行投资者交互上公布了其新第一代内窥镜手术机械人Hugo RAS。Hugo RAS食用功能组件化的彻底解决计划书，特别避免开刀刷卡机人直接费用和用的困难。

美敦力单位微小療法小队完成总监裁兼总栽鲍勃·怀特说：“这不只要仅是发布新闻一种新品上市机人，自己是要营造机人王国。”

之前14月29日，美敦力就官宣了以17亿欧元（相当于国民币120亿美金）收购网俄罗斯医学环保的设备工司Mazor Robotics及工具人輔助工具近视技术渠道，该工司重点品牌为Mazor X制导体系和Renaissance工具人輔助工具腰椎近视技术环保的设备。

在购买搞定后的一款月，美敦力在新加坡推行了Mazor X Stealth™POS机人辅助软件腰椎术手机平台。

Mazor X Stealth™ 服务器人软件系统将美敦力的Stealth手机软件与Mazor替换成的服务器人软件系统相综合。在数据交互式3D未来规划和消息软件系统带来了数据即时画面疏导，大数据可视化和汽车导航，带来了数据运行注意事项可分折性和灵活力性高性。它选择3D拍摄头，疏导标签和设备臂，以将持续监听器方法和测试仪器相比于脊椎的座位，并按记划明设手机定位因此。

美敦力最新信息第一次第首季（2020财年第一次第一次第首季）财务报表表示，在腰椎工作的提升中，技术服务器人正对腰椎工作提升做到拖拽效果。

在国内的，监管科室科室相同也在用力积极推进医疗服务卫生电脑人的应用。《我国国家制作业2025》中，生物制品生物制药和高耐腐蚀性医疗服务卫生医疗器具是要点的提升的世界十大各个领域之首。《2017-202一年我国国家术电脑人领域争夺现实状况及以后发展进步未来趋势通知单》体现 ，素我国的开刀POS机人的行业中规模较将在202在一年运到200亿。

而治疗广州POS机人对于那些骨外科植入式物市面的拉驱动力特别大，也成为几大骨外科国内巨头的必争的地方。

译文方式：

One of the hottest markets in the medical device industry right now is surgical robotics. The space, valued at $56.3 million in 2017, is expected to grow to $98,737 million by 2024 with a CAGR of 8.5% during the forecast, according to a report from Allied Market Research. Growth is happening now and 2019 has been a breakout year for surgical robotics – from product unveilings to delays. MD+DI is counting down the Top 7 developments for Surgical Robotics in 2019.

The Art of Negotiation

For years Intuitive Surgical has been at the top of the surgical robotics market – having gained a nod from FDA for the da Vinci Robot in 2000. (Whew that’s a lot of lead time.) However, competitors are>increased price negotiations and elongated negotiation timelines as competition gets closer to launching new products. The company said these dynamics could also result in profit fluctuations. This could be a plus for some hospitals and healthcare centers that have had issues with the da Vinci’s pricing.

CMR’s Two Big Wins

Cambridge, UK-based CMR has had a good year. In September, the company raised $243 million (wow!) in a Series C round to commercialize its Versius robot-assisted surgery device. And then last month the company completed the sale of its first unit to the Galaxy Care Hospital in Pune, India. CMR was founded 5 years ago and has publicly stated in media outlets that it hopes to have a nod from FDA next year.

Verb’s New Leadership

Verb is a joint venture between Johnson & Johnson’s Ethicon Unit and Verily Life Sciences. The collaboration happened during the time when Verily (the former life sciences unit of Google) was partnering with numerous companies in the medtech and pharmaceutical space. While Verb made a big splash when it was first formed, the company has been fairly quiet in 2019. However, in June Verb>

When Titan Hit Pause

Titan Medical hit a huge roadblock with the Sport robotic surgical system and announced in mid-October that it was withdrawing all forecasts with respect to the cost and timing of the platform. The Toronto-based company said a lack of financing was the reason behind the delay. Titan isn’t letting this stop it, however. The company is seeking to raise $25 million in an offering that could help get the Sport’s system back>

XACT Brings Home OK from FDA

XACT Robotics secured a coveted FDA nod for its robotic system. The device was cleared for use during CT-guided percutaneous interventional procedures. The wow factor behind the Caesarea, Isreal-based company’s robot is that it is the first hands-free robotic system combining image-based planning and navigation with the insertion and steering of various instruments across an array of clinical applications and indications.

Johnson & Johnson’s Glow Up in Surgical Robotics

Johnson & Johnson pulled off>Frederic Moll, M.D., CEO and Founder of Auris Health, joined J&J. Moll is also known for cofounding Intuitive Surgical. With this acquisition and J&J’s Verb the company now has multiple shots>

Medtronic’s Done Dropping Hints

Medtronic teased us all year long with tidbits and hints about its upcoming soft-tissue surgical robotics system. After some delays in 2018 with scant details about the platform, the Dublin-based company opened up a bit in June with the announcement of a collaboration with Karl Storz. The firm said its upcoming robotic-assisted surgical platform would incorporate Karl Storz’s 3D vision systems and visualization components. To boot the two companies had been working style="box-sizing: border-box; background-color: transparent; color: rgb(0, 184, 214); text-decoration: none; font-weight: bold;">announced in August it would unveil the robot during an investor’s meeting in September. And that it did. After a lengthy demonstration, Medtronic said it anticipates submitting for CE mark in the Q1 of the company's fiscal year 2021 (Medtronic's fiscal year begins in April), and filing for a U.S. investigational device exemption to begin placing systems in U.S. hospitals, training surgeons, and gathering clinical data in the first half of its fiscal year 2021. If all goes as planned, the system could be available both in Europe and in the U.S. within the next 24 months.